LCL1 Antibody

What is LCLAT1 and what are its primary functions?

LCLAT1 (Lysocardiolipin acyltransferase 1) is an enzyme that exhibits multiple acyltransferase activities. Its primary function involves acyl-CoA:lysocardiolipin acyltransferase (ALCAT) activity, which catalyzes the reacylation of lyso-cardiolipin to cardiolipin (CL), a key step in CL remodeling . The enzyme recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors .

Additionally, LCLAT1 exhibits 1-acyl-sn-glycerol-3-phosphate acyltransferase (AGPAT) activity, converting lysophosphatidic acid (LPA) into phosphatidic acid (PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone . It also possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities . Beyond its enzymatic functions, LCLAT1 is required for the establishment of hematopoietic and endothelial lineages .

What are the common alternative names for LCLAT1 in scientific literature?

LCLAT1 appears in scientific literature under several alternative designations that researchers should be aware of when conducting literature searches or interpreting research findings:

• AGPAT8 (1-acylglycerol-3-phosphate O-acyltransferase 8)

• ALCAT1 (Acyl-CoA:lysocardiolipin acyltransferase 1)

• LYCAT

• UNQ1849/PRO3579

• 1-AGP acyltransferase 8

• 1-AGPAT 8

Understanding these alternative nomenclatures is crucial when performing comprehensive literature reviews, as publications may use different terms to refer to the same protein.

What applications are commercially available LCLAT1 antibodies validated for?

Based on the available data, commercial LCLAT1 antibodies have been validated for several research applications:

• Western Blot (WB): For detecting LCLAT1 protein in cellular and tissue lysates under denaturing conditions

• Immunohistochemistry on paraffin-embedded tissues (IHC-P): For visualizing LCLAT1 expression in fixed tissue sections

• Immunocytochemistry (ICC): For detecting LCLAT1 in cultured cells

The specific antibodies mentioned in the search results (ab153987 and ab122197) have been validated for these applications with human samples . When selecting an antibody for research purposes, it's essential to verify that it has been validated for your specific application and target species.

How does LCLAT1 contribute to mitochondrial function through cardiolipin remodeling?

LCLAT1 plays a critical role in mitochondrial function through its involvement in cardiolipin remodeling. As an acyl-CoA:lysocardiolipin acyltransferase, it catalyzes the reacylation of lyso-cardiolipin to cardiolipin, which constitutes a key step in the cardiolipin remodeling process . This process is essential for maintaining proper mitochondrial membrane composition and function.

The enzyme shows preference for specific acyl donors, particularly linoleoyl-CoA and oleoyl-CoA , which influences the fatty acid composition of the resulting cardiolipin molecules. This specificity is physiologically significant because the fatty acid composition of cardiolipin directly affects its functional properties and, consequently, mitochondrial function.

Researchers investigating mitochondrial dysfunction in various pathological conditions should consider LCLAT1 as a potential target for study. Alterations in LCLAT1 activity could potentially contribute to mitochondrial dysfunction through disrupted cardiolipin remodeling, which might be relevant in conditions like neurodegenerative diseases, metabolic disorders, and cardiovascular diseases where mitochondrial dysfunction is implicated.

What similarities and differences exist between LCLAT1 and CLL-1 in research contexts?

There appears to be some confusion in terminology between LCLAT1 and CLL-1, which are distinct molecules with different functions and research applications:

LCLAT1 (Lysocardiolipin acyltransferase 1):

• Function: An enzyme involved in lipid metabolism, particularly cardiolipin remodeling and phospholipid synthesis

• Research applications: Studied in contexts related to mitochondrial function, lipid metabolism, and cellular development

• Research tools: Antibodies against LCLAT1 are used for detecting and studying the protein in various experimental settings

CLL-1 (C-type lectin-like molecule-1):

• Function: A cell surface molecule prevalent in acute myeloid leukemia (AML)

• Research applications: Studied as a potential therapeutic target for AML treatment approaches

• Research tools: Bispecific antibodies targeting CLL-1 and CD3 have been developed as potential therapeutic agents for AML

Understanding these distinctions is crucial for researchers to correctly identify their target of interest and design appropriate experimental approaches. While both may be studied using antibody-based techniques, their biological contexts and research applications differ significantly.

How can researchers evaluate LCLAT1 expression changes in developmental contexts?

Given LCLAT1's role in hematopoietic and endothelial lineage establishment , evaluating its expression changes during development requires specialized methodological approaches:

Temporal expression analysis:

• Timeline studies tracking LCLAT1 expression across developmental stages

• Correlation with developmental markers for hematopoietic and endothelial lineages

• RNA and protein quantification at critical developmental windows

Spatial expression analysis:

• Immunohistochemistry to localize LCLAT1 in developing tissues

• Co-localization studies with lineage-specific markers

• In situ hybridization for mRNA expression patterns

Functional correlation studies:

• Correlation between LCLAT1 expression levels and functional parameters of lineage commitment

• Assessment of mitochondrial function parameters during differentiation

• Analysis of lipid profiles during developmental transitions

When interpreting developmental expression data, researchers should consider both transcriptional and post-transcriptional regulation mechanisms, as well as the potential influence of tissue microenvironment on LCLAT1 expression and function.

What experimental controls should be included when using LCLAT1 antibodies?

Proper experimental controls are critical for ensuring the validity and reliability of results when using LCLAT1 antibodies:

Positive controls:

• Tissues or cell lines known to express LCLAT1 (e.g., tissues with high mitochondrial content)

• Recombinant LCLAT1 protein (if available)

• Samples with verified LCLAT1 overexpression

Negative controls:

• Primary antibody omission: Complete the staining procedure without adding the primary LCLAT1 antibody

• Isotype control: Use an irrelevant antibody of the same isotype and concentration

• Samples with verified LCLAT1 knockdown or knockout (if available)

Blocking peptide control:

• Pre-incubate the LCLAT1 antibody with its immunizing peptide before application to samples

• This should abolish specific staining if the antibody is truly specific

Cross-validation:

• Use multiple antibodies targeting different epitopes of LCLAT1

• Compare results across different detection methods (e.g., immunoblotting vs. immunostaining)

These controls help validate the specificity of antibody binding and ensure that observed signals genuinely represent LCLAT1 expression rather than artifacts or non-specific binding.

How should Western blot procedures be optimized for detecting LCLAT1?

Optimizing Western blot procedures for LCLAT1 detection requires careful consideration of several technical parameters:

Sample preparation:

• Include protease inhibitors to prevent degradation

• Use appropriate lysis buffers that efficiently extract membrane-associated proteins

• Determine optimal protein loading amount (typically 20-50 μg of total protein)

Gel electrophoresis:

• Use an appropriate percentage acrylamide gel based on LCLAT1's molecular weight

• LCLAT1 has a molecular weight of approximately 48-52 kDa, so a 10-12% gel would be suitable

Transfer conditions:

• Optimize transfer time and voltage for proteins in this molecular weight range

• Consider using PVDF membranes for better protein retention

Antibody incubation:

• Determine optimal primary antibody dilution through titration experiments

• Use appropriate blocking buffers to minimize background

• Optimize incubation time and temperature

Data table for Western blot optimization parameters:

Systematic optimization of these parameters will help ensure reliable and reproducible detection of LCLAT1 in Western blot experiments.

What are the key considerations when designing experiments to investigate LCLAT1 role in cardiolipin metabolism?

Designing experiments to investigate LCLAT1's role in cardiolipin metabolism requires multifaceted approaches:

Genetic modulation strategies:

• CRISPR/Cas9-mediated knockout of LCLAT1

• siRNA or shRNA knockdown for transient or stable reduction

• Overexpression systems with wild-type or mutant LCLAT1

• Site-directed mutagenesis of key catalytic residues

Functional assessments:

• Cardiolipin content and composition analysis by mass spectrometry

• Mitochondrial function parameters (membrane potential, respiration, ATP production)

• Cellular stress responses under conditions that challenge mitochondrial function

• Cell viability and proliferation in contexts requiring mitochondrial adaptation

Experimental design considerations:

• Selection of appropriate cell types (those with high mitochondrial content or dependency)

• Time-course studies to capture dynamic changes in cardiolipin metabolism

• Stress conditions (e.g., oxidative stress, nutrient deprivation) to reveal conditional phenotypes

• Rescue experiments to confirm specificity of observed effects

Data table for experimental approaches:

These experimental approaches provide a comprehensive framework for investigating LCLAT1's role in cardiolipin metabolism and its functional consequences.

How should researchers analyze immunohistochemistry data for LCLAT1 expression in tissue samples?

Analyzing immunohistochemistry data for LCLAT1 expression requires systematic approaches to ensure objectivity and reproducibility:

Qualitative analysis:

• Subcellular localization pattern (expected to be primarily mitochondrial/cytoplasmic)

• Distribution within tissue architecture (cell-type specific expression)

• Staining intensity variations across different regions

• Comparison with known expression patterns from literature

Quantitative analysis:

• Scoring systems for staining intensity (0-3+ scale)

• Percentage of positive cells in representative fields

• H-score calculation (intensity × percentage positive cells)

• Digital image analysis using appropriate software for unbiased quantification

Comparative analysis:

• Between different tissue types or developmental stages

• Between normal and pathological samples

• Correlation with other markers of interest

Validation approaches:

• Confirmation of findings with alternative detection methods (e.g., Western blot, qPCR)

• Independent assessment by multiple observers to ensure reproducibility

• Statistical analysis of quantitative data with appropriate tests

When interpreting LCLAT1 immunohistochemistry data, researchers should consider potential technical artifacts, the specificity of the antibody used, and the biological context of the tissues being examined.

What considerations are important when comparing data from different anti-LCLAT1 antibodies?

When comparing data generated using different anti-LCLAT1 antibodies, researchers should consider several important factors:

Epitope differences:

• Different antibodies may target distinct regions of LCLAT1 (e.g., ab153987 targets aa 150 to C-terminus)

• Epitope accessibility may vary depending on protein conformation and application

• Post-translational modifications may affect epitope recognition

Validation status:

• Extent of validation for specific applications (WB, IHC, ICC)

• Validation in relevant species and cell/tissue types

• Availability of published data supporting antibody specificity

Technical parameters:

• Differences in optimal working conditions (dilution, incubation time)

• Variations in detection methods (direct vs. indirect, fluorescent vs. chromogenic)

• Batch-to-batch variability within the same catalog number

Data reconciliation approaches:

• Direct side-by-side comparison using identical samples and protocols

• Validation with orthogonal methods (e.g., genetic knockdown)

• Analysis of staining pattern consistency with known biology

When discrepancies are observed between different antibodies, researchers should prioritize data from the most extensively validated antibody or consider using multiple antibodies in parallel to increase confidence in the findings.

How can researchers meaningfully interpret LCLAT1 expression changes in disease contexts?

Interpreting LCLAT1 expression changes in disease contexts requires careful consideration of multiple factors:

Mechanistic relevance:

• Connect changes to LCLAT1's known biological functions (cardiolipin remodeling, phospholipid synthesis)

• Consider impact on mitochondrial function in the disease context

• Evaluate potential consequences for hematopoietic/endothelial development if relevant

Causality assessment:

• Determine whether expression changes are likely causes or consequences of the disease

• Analyze temporal relationship between LCLAT1 changes and disease progression

• Consider genetic evidence linking LCLAT1 to the disease (e.g., mutations, SNPs)

Quantitative considerations:

• Magnitude of expression changes and statistical significance

• Consistency across patient samples or experimental models

• Correlation with disease severity or clinical parameters

Biological context:

• Cell type-specific expression changes within heterogeneous tissues

• Compensatory mechanisms that may mask functional consequences

• Interaction with other disease-relevant pathways

Researchers should integrate LCLAT1 expression data with functional studies to establish the biological significance of observed changes and their potential relevance as diagnostic markers or therapeutic targets.

What are common problems encountered when using LCLAT1 antibodies and how can they be resolved?

Researchers frequently encounter several technical challenges when working with LCLAT1 antibodies:

High background in immunostaining:

• Problem: Non-specific binding causing diffuse background staining

• Solutions: Increase blocking time (2+ hours), use alternative blocking reagents (BSA vs. serum), increase washing duration and stringency, optimize antibody dilution through titration experiments

Weak or absent signal in Western blots:

• Problem: Inefficient detection of LCLAT1 protein

• Solutions: Increase protein loading, optimize extraction method for membrane-associated proteins, verify antibody reactivity with positive control, enhance sensitivity with amplification systems

Multiple bands in Western blots:

• Problem: Detection of non-specific bands or degradation products

• Solutions: Include protease inhibitors during sample preparation, compare with positive control sample, optimize blocking and washing conditions, consider using different antibody targeting alternate epitope

Inconsistent results between experiments:

• Problem: Variable outcomes despite seemingly identical protocols

• Solutions: Standardize all protocol steps, prepare larger batches of working solutions, monitor incubation temperatures precisely, establish detailed SOPs for critical steps

Data table for troubleshooting common issues:

Systematic troubleshooting approaches will help researchers resolve technical issues and generate reliable data with LCLAT1 antibodies.

What strategies can improve the specificity of LCLAT1 detection in complex tissue samples?

Improving the specificity of LCLAT1 detection in complex tissue samples requires specialized approaches:

Antigen retrieval optimization:

• Test multiple antigen retrieval methods (heat-induced vs. enzymatic)

• Optimize retrieval conditions (pH, temperature, duration)

• Consider dual retrieval approaches for challenging samples

Signal amplification with specificity control:

• Tyramide signal amplification (TSA) for low-abundance detection

• Polymer-based detection systems with lower background

• Proximity ligation assay (PLA) for highly specific detection

Multiplexed staining approaches:

• Co-staining with mitochondrial markers to confirm expected localization

• Sequential staining with multiple LCLAT1 antibodies targeting different epitopes

• Dual validation with fluorescent and chromogenic detection systems

Sample preparation refinements:

• Section thickness optimization (thinner sections for better antibody penetration)

• Enhanced permeabilization for improved antibody access

• Background-reducing tissue treatments (e.g., Sudan Black B for autofluorescence)

Controls for specificity validation:

• Peptide competition assays with immunizing peptide

• Comparison with mRNA expression (RNAscope or in situ hybridization)

• Genetic manipulation models (if available) as gold-standard controls

These strategies, when systematically applied, can significantly improve the specificity and reliability of LCLAT1 detection in complex tissue samples.

How can researchers design experiments to validate LCLAT1 antibody specificity?

Designing rigorous experiments to validate LCLAT1 antibody specificity is essential for generating reliable research data:

Genetic approach validation:

• CRISPR/Cas9 knockout of LCLAT1 as negative control

• siRNA knockdown with quantitative assessment of signal reduction

• Overexpression system as positive control

• Rescue experiments with wild-type vs. mutant LCLAT1

Biochemical validation:

• Immunoprecipitation followed by mass spectrometry to confirm target identity

• Peptide competition assays with titrated amounts of immunizing peptide

• Pre-adsorption tests with recombinant LCLAT1 protein

• Western blot with size-appropriate band detection

Cross-antibody validation:

• Comparison of staining patterns between antibodies targeting different LCLAT1 epitopes

• Correlation between results obtained with different antibodies

• Evaluation of subcellular localization consistency with known biology

Data table for antibody validation experiments:

A comprehensive validation approach incorporating multiple complementary methods provides the strongest evidence for antibody specificity and supports confidence in research findings.